SCHEMBL6941312

SCHEMBL6941312

COc1cc(CNC(=O)c2cc(S(C)(=O)=O)ccc2N[C@H]2CC[C@H](O)CC2)ccc1Cl

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 1/20 0.44
KMT2A Q03164 1/20 0.44
LMNA P02545 6/20 0.43
ALDH1A1 P00352 2/20 0.41
HPGD P15428 2/20 0.40
KCNH2 Q12809 2/20 0.39
ADRA2A P08913 1/20 0.39
CYP2D6 P10635 1/20 0.39
CYP2C9 P11712 1/20 0.39
DRD2 P14416 1/20 0.39
TSHR P16473 1/20 0.39
DRD3 P35462 1/20 0.39
HTR2B P41595 1/20 0.39
STAT6 P42226 1/20 0.39
BLM P54132 1/20 0.39
TYRO3 Q06418 2/20 0.39
MERTK Q12866 2/20 0.39
AXL P30530 1/20 0.39
MAPK1 P28482 1/20 0.39
SMN1; SMN2 Q16637 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6941310 1.00 MEN1 (0.44) MEN1KMT2ALMNAALDH1A1HPGD
SCHEMBL7366356 0.84 FLT3 (0.44) LMNAHPGDTYRO3MERTKFLT3
SCHEMBL7404535 0.84 PDE5A (0.51) LMNATYRO3MERTKFLT3GAS6
SCHEMBL7404538 0.84 PDE5A (0.51) LMNATYRO3MERTKFLT3GAS6
SCHEMBL7366354 0.84 FLT3 (0.44) LMNAHPGDTYRO3MERTKFLT3
SCHEMBL6943992 0.80 ALDH1A1 (0.54) MEN1KMT2AALDH1A1SMN1; SMN2
SCHEMBL6943987 0.80 ALDH1A1 (0.54) MEN1KMT2AALDH1A1SMN1; SMN2
SCHEMBL6941322 0.80 PDE5A (0.52) MEN1KMT2ASMN1; SMN2
SCHEMBL6941319 0.80 PDE5A (0.52) MEN1KMT2ASMN1; SMN2
SCHEMBL6944497 0.80 PDE5A (0.52) MEN1KMT2ASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1080069-B1 ANTHRANILIC ACID DERIVATIVES AS INHIBITORS OF THE CGMP-PHOSPHODIESTERASE FUJISAWA PHARMACEUTICAL CO (JP) 2003-03-19 EP disclosed
US-20020193614-A1 Anthranilic acid derivatives as inhibitors of the CGMP-phosphodiesterase FUJISAWA PHARMACEUTICAL CO. LTD. (JP) 2002-12-19 US disclosed
US-6384080-B1 TREATMENT AND/OR PREVENTION OF CERTAIN CARDIOVASCULAR DISORDERS, UROGENITAL DISORDERS, RESPIRATORY SYSTEM DISORDERS, DISORDERS OF GUT MOTILITY, SEXUAL DISORDERS, DIABETIC COMPLICATIONS, URTICARIA FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2002-05-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020193614-A1 Anthranilic acid derivatives as inhibitors of the CGMP-phosphodiesterase PDE3A, PDE2A, PDE5A MEN1 2660/4885KMT2A 1991/4885LMNA 1858/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.